Form 4: Y-mAbs Therapeutics Executive Granted Stock Options

Douglas J. Gentilcore, SVP and Danyelza Business Unit Head at Y-mAbs Therapeutics, was granted 142,600 stock options on January 17, 2025.

Summary

• Douglas J. Gentilcore, a Senior Vice President at Y-mAbs Therapeutics, was granted 142,600 stock options.
• The options were granted under the company's 2018 Equity Incentive Plan.
• The exercise price of the options is $6.16 per share.
• The options vest over time, with 25% vesting on January 17, 2026, and the remainder vesting monthly until fully vested.
• The options expire on January 17, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with company performance.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• Vesting schedules, such as the one described, are typical to ensure long-term commitment from executives.
• The specific terms of the grant, such as the exercise price and vesting schedule, are likely comparable to those offered by similar companies in the sector, such as BioMarin Pharmaceutical or Regeneron Pharmaceuticals.

Stakeholder Impact

• The stock option grant may have a minor positive impact on shareholder sentiment as it aligns executive interests with company performance.

Key Dates

Keywords

stock options, equity incentive plan, executive compensation, vesting, Y-mAbs Therapeutics, Douglas J. Gentilcore